Literature DB >> 16478292

Augmenting strategies in clozapine-resistant schizophrenia.

Gary Remington, Amitabha Saha, Siow-Ann Chong, Chekkera Shammi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16478292     DOI： 10.2165/00023210-200620020-00008

Source DB:  PubMed          Journal:  CNS Drugs        ISSN： 1172-7047            Impact factor:   5.749


× No keyword cloud information.
  4 in total

1.  A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms.

Authors:  Malcolm Peet; David F Horrobin
Journal:  J Psychiatr Res       Date:  2002 Jan-Feb       Impact factor: 4.791

Review 2.  Augmentation strategies in clozapine-resistant schizophrenia.

Authors:  Gary Remington; Amitabha Saha; Siow-Ann Chong; Chekkera Shammi
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 3.  Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review.

Authors:  Vassilis P Kontaxakis; Panayotis P Ferentinos; Beata J Havaki-Kontaxaki; Dimitris K Roukas
Journal:  Eur Psychiatry       Date:  2005-08       Impact factor: 5.361

4.  Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia.

Authors:  Robin Emsley; Christo Myburgh; Pieter Oosthuizen; Susan J van Rensburg
Journal:  Am J Psychiatry       Date:  2002-09       Impact factor: 18.112
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.